No connection

Search Results

ABBV vs QIPT

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
QIPT
Quipt Home Medical Corp
BEARISH
Price
$3.65
Market Cap
$162.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
QIPT
--
Forward P/E
ABBV
15.42
QIPT
182.5
P/B Ratio
ABBV
-146.66
QIPT
1.59
P/S Ratio
ABBV
6.5
QIPT
0.61
EV/EBITDA
ABBV
15.27
QIPT
6.41

Profitability

Gross Margin
ABBV
71.46%
QIPT
72.38%
Operating Margin
ABBV
35.5%
QIPT
1.54%
Profit Margin
ABBV
4.0%
QIPT
-4.03%
ROE
ABBV
137.96%
QIPT
-9.31%
ROA
ABBV
9.59%
QIPT
-0.83%

Growth

Revenue Growth
ABBV
9.1%
QIPT
32.0%
Earnings Growth
ABBV
-88.7%
QIPT
--

Financial Health

Debt/Equity
ABBV
--
QIPT
1.02
Current Ratio
ABBV
0.72
QIPT
1.04
Quick Ratio
ABBV
0.47
QIPT
0.6

Dividends

Dividend Yield
ABBV
3.05%
QIPT
--
Payout Ratio
ABBV
490.15%
QIPT
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
QIPT BEARISH

QIPT exhibits significant financial fragility, highlighted by a weak Piotroski F-Score of 3/9 and a concerning Quick Ratio of 0.60. While revenue growth is robust at 32% YoY, the company struggles with consistent profitability and a track record of missing earnings estimates. The current valuation is disconnected from fundamentals, evidenced by an extreme Forward P/E of 182.50. Despite a recent price rally to 52-week highs, the underlying deterministic health metrics suggest a high risk of regression.

Strengths
Strong Gross Margin of 72.38%
Robust YoY Revenue Growth of 32.00%
Low Price-to-Sales ratio (0.61)
Risks
Weak financial health (Piotroski F-Score 3/9)
Poor liquidity position (Quick Ratio 0.60)
Extreme Forward P/E ratio of 182.50

Compare Another Pair

ABBV vs QIPT: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Quipt Home Medical Corp (QIPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile